Global Central Nervous System Disorders Therapeutics Market 2016-2020
Overview of the central nervous system (CNS) disorders therapeutics market
The market research analyst at Technavio predicts that the global central nervous system (CNS) disorders therapeutics market will grow steadily and post a CAGR of approximately 3% by 2020. One of the factors contributing to the growth of the market will be the allotment of special regulatory designations for CNS disorders. The designations assigned to drugs by the US FDA (Food and Drug Administration) and EMA (European Medicines Agency) help in the faster entry of these drugs into the market for the treatment of serious conditions. Currently, in the US, orphan drugs are offered incentives such as tax credits for clinical testing, exemption from prescription fees, and market exclusivity for seven years. Recently, the US FDA granted a breakthrough therapy designation for Roche’s investigational drug, Ocrelizumab, for the treatment of primary progressive multiple sclerosis.
One of the recent trends in the market is the increasing focus on regenerative therapies for CNS disorders. These therapies help in the healing process by replacement or regeneration of human cells, tissues or organs, and various regenerative therapies, including stem cells, growth factors, and the use of a matrix such as fibrin, collagen, and hyaluronic acid. Consequently, various vendors have strted engaging in the development of regenerative medicines with the help of advancements in technology and product innovation.
Competitive landscape and key vendors
In this market, many existing and emerging companies have started launching grounding breaking products and medicines to cure certain ailments. Major vendors are increasingly pursuing strategic initiatives to drive growth, profitability, and boost their market shares. To gain maximum market shares, the new entrants focus on developing novel drugs and forming strategic partnerships.
Key vendors in the market are -
- Eli Lilly
- Janssen Pharmaceuticals
Other prominent vendors are AB Science, AbbVie, Abital Pharma, Acorda Therapeutics, Active Biotech, Adamas Pharmaceuticals, Addex Therapeutics, Akorn, Alcobra, Alexza Pharmaceuticals, Alkermes, Amarantus, Aprecia Pharmaceuticals, Archer Pharmaceuticals, Astellas, AstraZeneca, Aurobindo Pharma, Auspex Pharmaceuticals, Avanir Pharmaceuticals, Biscayne Pharmaceuticals, Boehringer Ingelheim, Cerecor, Chugai Pharmaceutical, Concordia, Convergence Pharmaceuticals, Curemark, CURx Pharmaceuticals, Dainippon Sumitomo Pharma, Dart NeuroScience, Delpor, Desitin Arzneimittel, D-Pharm, Dr. Reddy's Laboratories, Edgemont Pharmaceuticals, Endo International, E-Therapeutics, Euthymics, Evotec, F. Hoffmann-La Roche, Fabre-Kramer, Forum Pharmaceuticals, Gedeon Richter, Glenmark, Grupo Ferrer Internacional, GW Pharmaceuticals, GW Pharmaceuticals, Hisamitsu, Impax, Insero Health, INSYS Therapeutics, Intellipharmaceutics, Intra-Cellular Therapies, Intra-Cellular Therapies, Kyowa Hakko Kirin, Ipsen, Ligand Pharmaceuticals, Lundbeck, Lupin, Luye Pharma, MarcoPolo Pharmaceuticals, Marinus Pharmaceuticals, Meda AB, Merck, Mitsubishi Tanabe, MorphoSys AG, MSI Methylation Sciences, Mylan, Naurex, Neuralstem, Neurelis, Neurovance, Nobelpharma, Noven Pharmaceuticals, Omeros Corporation, Opexa, Opko Health, Orion, Ophelia Pharmaceutical, Otsuka Pharmaceuticals, Palobiofarma, Par Pharmaceuticals, Pierre Fabre, PNBDevCo, Prana Biotechnology, Raptor Pharmaceutical, Reviva Pharmaceuticals, Reviva Pharmaceuticals , Sanofi, SciFlour, Sedor Pharmaceuticals, Shire, Siena Biotech, SK Biopharmaceuticals, SOM Biotech, Somerset Pharmaceuticals, STADA Arzneimittel, Sun Pharmaceutical, Sunovion Pharmaceuticals (US), Supernus Pharmaceuticals, Suven, Takeda Pharmaceuticals, Teva Pharmaceuticals, Torrent Pharmaceuticals, Tris Pharma, Turing Pharmaceuticals, UCB, US WorldMeds, Valeant Pharmaceuticals, Zinfandel Pharmaceuticals, and Zogenix.
Segmentation based on the type of disease and analysis of the CNS disorders therapeutics market
- Depression drugs market
- MS (Multiple sclerosis) drugs market
- Bipolar disorder drugs market
- Schizophrenia drugs market
- Epilepsy drugs market
- AD (Alzheimer's disease) drugs market
- Parkinson’s drugs market
During 2015, the depression drugs segment dominated the market by accounting for around 20% of the total market share. The extensive use of complementary and alternative medicines (CAM), such as homeopathic and naturopathic medications, have augmented the need for CNS therapeutics to treat depressions during the forecast period.
Segmentation based on geography and analysis of the CNS disorders therapeutics market
Market researchers predict that the Americas will dominate the market by posting a CAGR of approximately 3% by 2020. Some of the factors contributing towards the growth of this market in the Americas will be the vendor’s expertise in manufacturing high-quality and cost-efficient CNS drugs and their capability to develop advanced analytical capabilities. In addition, factors such as the special regulatory designation for CNS disorders and increasing collaborations with Latin American countries will help also help in the evolution of the market.
Key questions answered in the report include
- What will the market size and the growth rate be in 2020?
- What are the key factors driving the global CNS disorders therapeutics market?
- What are the key market trends impacting the growth of the global CNS disorders therapeutics market?
- What are the challenges to market growth?
- Who are the key vendors in the global CNS disorders therapeutics market?
- What are the market opportunities and threats faced by the vendors in the global CNS disorders therapeutics market?
- Trending factors influencing the market shares of the Americas, APAC, and EMEA.
- What are the key outcomes of the five forces analysis of the global CNS disorders therapeutics market?
Technavio also offers customization on reports based on specific client requirement.
- Global Generic Drugs Market 2016-2020
- Global Transcriptomics Market 2016-2020
- Global Insomnia Market - Market Research Analysis 2015-2019
Central nervous system (CNS) disorder drugs include medications used for the treatment of diseases that affect the brain or spinal cord. CNS disorders include Parkinson’s disease, epilepsy, Alzheimer’s disease, anxiety, depression, and bipolar disorders. Epilepsy is a persistent brain ailment with recurring seizures, while Parkinson’s disease is a degenerative CNS disorder that includes rigidity, tremor, akinesia, and bradykinesia. Such diseases occur due to autoimmune disorders, neurodegeneration, tumors, trauma, and vascular disorders. CNS disorders can be segmented into psychiatry, neurology and pain drugs. Psychiatry drugs are broadly used for depression, anxiety, bipolar disorders, and attention deficit hyperactivity disorder (ADHD), and schizophrenia. Neurological drugs treat conditions such as epilepsy, migraine, Parkinson’s disease, multiple sclerosis, narcolepsy, and Alzheimer’s disease. The pain management drugs are used to treat pain related to CNS disorders.
The report, global CNS disorders therapeutics market, is part of Technavio’s healthcare and life sciences research portfolio. This portfolio provides a comprehensive market analysis along with the market share, market sizing, and market segmentations covering areas such as cardiovascular and metabolic disorders, central nervous system, oncology, medical imaging, life science research tools, and vaccines. These market research reports provide a perspective on the various market opportunities and market threats along with the key trends that would influence the market growth during the forecast period. It presents insights into the changing competitive landscape and a detailed profiling and market analysis of the vendors. Also covered in the research are the key regions or countries that would have an impact on the market during the assessment years.